cannabis dependence
cannabis dependence
Explore linked clinical trials. Standard reference: MONDO:0005689132 results · Page 1 of 6
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cannabis and Opioid Use Disorder, Study 2 | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, cannabis dependence, opiate dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 1 | 2026-10-09 | NCT07661446 | |
| Tolerability and Efficacy of CBD Extract for RLS Treatment | Chemically-Induced Disorders, Dyssomnias, Parasomnias, Sleep Disorders, Intrinsic, cannabis dependence, nervous system disorder, psychiatric disorder, restless legs syndrome, sleep-wake disorder, substance-related disorder | Not yet recruiting | Phase 2 | 2026-10-08 | NCT07224932 | |
| Clinician Practice Companion to Address Youth Substance Use | Chemically-Induced Disorders, Drug Misuse, Drug Overdose, Narcotic-Related Disorders, Opioid Use Disorder, Prescription Drug Misuse, Substance Use, cannabis dependence, opiate dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Not applicable | 2026-10-07 | NCT07725289 | |
| Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Early phase 1 | 2026-10-06 | NCT07694466 | |
| Cannabis' Impact on Alcohol Consumption | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol-related disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-10-05 | NCT05389930 | |
| NTI164 in Autism Spectrum Disorder | Chemically-Induced Disorders, autism, autism spectrum disorder, cannabis dependence, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 3 | 2026-09-30 | NCT07257939 | |
| Clinical Trial on Agitation in Alzheimer's Dementia | Alzheimer disease, Chemically-Induced Disorders, Dyskinesias, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychomotor Agitation, Psychomotor Disorders, Signs and Symptoms, anxiety disorder, brain disorder, cannabis dependence, central nervous system disorder, cognitive disorder, dementia, depressive disorder, nervous system disorder, neurodegenerative disease, psychiatric disorder, substance-related disorder, tauopathy | Active, not recruiting | Phase 2 | 2026-09-30 | NCT05543681 | |
| Acute Effects of Cannabis on Cognition and Affect | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-09-29 | NCT07296874 | |
| Pregnenolone as a Treatment for Cannabis Intoxication | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-09-29 | NCT07216690 | |
| Delayed-Release, Extended-Release Methylphenidate (Jornay PM) for Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder and Cannabis Use Disorder | Chemically-Induced Disorders, attention deficit hyperactivity disorder, inattentive type, cannabis dependence, neurodevelopmental disorder, oppositional defiant disorder, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 4 | 2026-09-28 | NCT07838311 | |
| Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Early phase 1 | 2026-09-25 | NCT06334016 | |
| Oral and Topical Phytocannabinoids for Psoriasis | Chemically-Induced Disorders, Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, cannabis dependence, psoriasis, psychiatric disorder, skin disorder, substance-related disorder | Active, not recruiting | Phase 2 | 2026-09-24 | NCT07839455 | |
| Lemborexant for Cannabis Use Disorder | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-09-22 | NCT07802990 | |
| Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 2 | 2026-09-21 | NCT07468552 | |
| Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 1 | 2026-09-18 | NCT07214155 | |
| QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360) | Chemically-Induced Disorders, Cocaine-Related Disorders, Compulsive Sexual Behavior Disorder, Disruptive, Impulse Control, and Conduct Disorders, Gender Dysphoria, Genital Diseases, Narcotic Dependence, Narcotic-Related Disorders, Sexual Dysfunctions, Psychological, Sexual and Gender Disorders, Urogenital Diseases, alcohol abuse, alcohol-related disorders, atrial septal defect, attention deficit hyperactivity disorder, inattentive type, autism, autism spectrum disorder, autism spectrum disorder 1, cannabis dependence, cocaine abuse, neurodevelopmental disorder, opiate dependence, oppositional defiant disorder, pathological gambling, pervasive developmental disorder, physiological sexual disorder, psychiatric disorder, substance-related disorder | Not yet recruiting | Not applicable | 2026-09-17 | NCT07661823 | |
| Cannabidiol for Pain Relief of Patients With End-stage mCRPC | Chemically-Induced Disorders, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, cannabis dependence, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-09-16 | NCT07549256 | |
| Cannabis (THC vs. CBD) in Multiple Sclerosis | CNS demyelinating autoimmune disease, Chemically-Induced Disorders, autoimmune disease, autoimmune disorder of the nervous system, cannabis dependence, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder, psychiatric disorder, substance-related disorder | Recruiting | Phase 2 | 2026-09-15 | NCT06261489 | |
| Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use | Chemically-Induced Disorders, Cognition Disorders, Cognitive Dysfunction, Memory Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Signs and Symptoms, cannabis dependence, cognitive disorder, nervous system disorder, psychiatric disorder, schizophrenia, substance-related disorder | Recruiting | Not applicable | 2026-09-15 | NCT05445180 | |
| Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Not stated | 2026-09-10 | NCT07459270 | |
| Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome | Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Rett syndrome, X-linked disease, cannabis dependence, hereditary disease, inherited neurodegenerative disorder, intellectual disability, nervous system disorder, psychiatric disorder, substance-related disorder | Not yet recruiting | Phase 2 / Phase 3 | 2026-09-09 | NCT07257978 | |
| Analgesic and Subjective Effects of Terpenes | Chemically-Induced Disorders, Drug Abuse, Neurobehavioral Manifestations, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agnosia, cannabis dependence, nervous system disorder, perceptual disorders, psychiatric disorder, substance-related disorder | Active, not recruiting | Phase 1 | 2026-09-08 | NCT04451863 | |
| High Potency Cannabis: Acute and Protracted Effects | Chemically-Induced Disorders, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 1 | 2026-09-04 | NCT06859723 | |
| The Pharmacokinetics of a Hemp-Based Topical Product | Chemically-Induced Disorders, cannabis dependence, psychiatric disorder, substance-related disorder | Recruiting | Phase 1 | 2026-09-03 | NCT07603518 | |
| Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department | Chediak-Higashi syndrome, Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Hemic and Lymphatic Diseases, Primary Immunodeficiency Diseases, albinism, cannabinoid hyperemesis syndrome, cannabis dependence, eye disorder, hematologic disorder, hereditary disease, immune system disorder, inborn error of immunity, leukocyte disorder, phagocyte bactericidal dysfunction, psychiatric disorder, substance-related disorder | Not yet recruiting | Early phase 1 | 2026-09-01 | NCT07726069 |